ALDESLEUKIN , TIL cells clinical trials

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

This study looks at a new treatment called adoptive T cell therapy, combined with a low dose of a medicine called IL-2, for women with advanced ovarian cancer. It's an early-stage study testing how safe this treatment is.